Erratum: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer (Nature Reviews Drug Discovery (2006) vol. 5 (835-844) 10.1038/nrd2130);Discovery and development of sorafenib: A multikinase inhibitor for treating cancer

Nature Reviews Drug Discovery

Volumn 5, Issue 10, 2006, Pages 835-844

  Wilhelm, Scott ^a   Carter, Christopher ^a   Lynch, Mark ^a   Lowinger, Timothy ^a   Dumas, Jacques ^a   Smith, Roger A ^a   Schwartz, Brian ^a   Simantov, Ronit ^a   Kelley, Susan ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOISOXAZOLE; 3 THIENYLUREA; ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CGP 69846A; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RAF PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HIGH THROUGHPUT SCREENING; HUMAN; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; TUMOR VASCULARIZATION;

EID: 33749238553     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2262     Document Type: Erratum

References (92)

1. Tabin, C. J. et al. Mechanism of activation of a human oncogene. Nature 300, 143-149 (1982).
2. Parada, L. F., Tabin, C. J., Shih, C. & Weinberg, R. A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474-478 (1982).
3. Weinberg, R. A. Tumor suppressor genes. Science 254, 1138-1146 (1991).
4. Gallo, R. C. & Wong-Staal, F. Retroviruses as etiologic agents of some animal and human leukemias and lymphomas and as tools for elucidating the molecular mechanism of leukemogenesis. Blood 60, 545-557 (1982).
5. Varmus, H. Retroviruses. Science 240, 1427-1435 (1988).
6. Spector, D. H. et al. Uninfected avian cells contain RNA related to the transforming gene of avian sarcoma viruses. Cell 13, 371-379 (1978).
7. Bishop, J. M. Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52, 301-354 (1983).
8. Frost, P. & Kerbel, R. S. On a possible epigenetic mechanism(s) of tumor cell heterogeneity. The role of DNA methylation. Cancer Metastasis Rev. 2, 375-378 (1983).
9. Weinberg, R. A. The molecular basis of oncogenes and tumor suppressor genes. Ann. NY Acad. Sci. 758, 331-338 (1995).
10. Niman, H. L. Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor. Nature 307, 180-183 (1984).
11. Coussens, L. et al. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature 320, 277-280 (1986).
12. Schechter, A. L. et al. The neu oncogene: An erb-B-related gene encoding a 185, 000-Mr tumour antigen. Nature 312, 513-516 (1984).
13. Gill, G. N., Bertics, P. J. & Santon, J. B. Epidermal growth factor and its receptor. Mol. Cell Endocrinol. 51, 169-186 (1987).
14. Ishizawar, R. & Parsons, S. J. c-Src and cooperating partners in human cancer. Cancer Cell 6, 209-214 (2004).
15. Kranenburg, O. The KRAS oncogene: Past, present, and future. Biochim. Biophys. Acta 1756, 81-82 (2005).
16. Bos, J. L. Ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689 (1989).
17. Ponzielli, R., Katz, S., Barsyte-Lovejoy, D. & Penn, L. Z. Cancer therapeutics: Targeting the dark side of Myc. Eur. J. Cancer 41, 2485-2501 (2005).
18. Milde-Langosch, K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 41, 2449-2461 (2005).
19. Weiss, C. & Bohmann, D. Deregulated repression of c-Jun provides a potential link to its role in tumorigenesis. Cell Cycle 3, 111-113 (2004).
20. Kolch, W., Kotwaliwale, A., Vass, K. & Janosch, P. The role of Raf kinases in malignant transformation. Expert. Rev. Mol. Med. 2002, 1-18 (2002).
21. O'Neill, E., Rushworth, L., Baccarini, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267-2270 (2004).
22. Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000 (2002).
23. Salvatore, G. et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 5175-5180 (2004).
24. Melillo, R. M. et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115, 1068-1081 (2005).
25. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
26. Oka, H. et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55, 4182-4187 (1995).
27. Hwang, Y. H. et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol. Res. 29, 113-121 (2004).
28. McPhillips, F. et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br. J. Cancer 85, 1753-1758 (2001).
29. Mukherjee, R., Bartlett, J. M., Krishna, N. S., Underwood, M. A. & Edwards, J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 64, 101-107 (2005).
30. Kasid, U. & Dritschilo, A. RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22, 5876-5884 (2003).
31. Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocrine-Related Cancer 8, 219-225 (2001).
32. McDonald, O. B. et al. A scintillation proximity assay for the Raf/MEK/ ERK kinase cascade: High-throughput screening and identification of selective enzyme inhibitors. Anal. Biochem. 268, 318-329 (1999).
33. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493-502 (2002).
34. Dowell, J., Minna, J. D. & Kirkpatrick, P. Erlotinib hydrochloride. Nature Rev. Drug Discov. 4, 13-14 (2005).
35. Zhang, Z. et al. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am. J. Pharmacogenomics 5, 173-190 (2005).
36. Aherne, G. W., McDonald, E. & Workman, P. Finding the needle in the haystack: Why high-throughput screening is good for your health. Breast Cancer Res. 4, 148-154 (2002).
37. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
38. Riedl, B. et al. Potent Raf kinase inhibitors from the diphenylurea class: Structure activity relationships. Clin. Cancer Res 20, 83a (2001).
39. Smith, R. A. et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: Identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett. 11, 2775-2778 (2001).
40. Lowinger, T. B., Riedl, B., Dumas, J. & Smith, R. A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 8, 2269-2278 (2002).
41. Wilhelm, S. et al. BAY 43-9006, a novel Raf-1 kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells. Proc. Am. Assoc. Cancer Res. 42, 923 (2001).
42. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
43. Carlomagno, F. et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98, 326-334 (2006).
44. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
45. Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243 (2002).
46. Sharma, A. et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412-2421 (2005).
47. Chang, Y. S. et al. BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Clin. Cancer Res. 46, 5831 (2005).
48. Liu, L. et al. Sorafenib (BAY 43-9006) inhibits the Raf/MEK/ERK pathway in hepatocelluiar carcinoma (HCC) cells and produces robust efficacy against PLC/PRF/5 HCC tumors in mice. Poster presentation Am. Assoc. Cancer Res.-Natl Cancer Inst.-Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
49. Yu, C. et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869 (2005).
50. Rahmani, M., Maynard Davis, E., Bauer, C., Dent, P. & Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227 (2005).
51. Panka, D. J., Wang, W., Atkins, M. B. & Mier, J. W. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66, 1611-1619 (2006).
52. Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005).
53. Clark, J. W., Eder, J. P., Ryan, D., Lee, R. & Lenz, H.-J. The safety and pharmacokinetics of the multi-targeted tyrosine kinase inhibitor (including Raf kinase and VEGF kinase), BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005).
54. Awada, A. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861 (2005).
55. Moore, M. et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol. 16, 1688-1694 (2005).
56. Strumberg, D. et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur. J. Cancer 42, 548-556 (2006).
57. Kupsch, P. et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5, 188-196 (2005).
58. Figer, A. et al. Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors. Ann. Oncol 15, iii87 (2004).
59. Flaherty K. T. et al. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: PFS and response versus B-Raf status. Proc. 4th Intl. Symp. Targeted Anticancer Ther. Amsterdam, The Netherlands [online]. (2006).
60. Siu, L. L. et al. Phase I/II trial of sorafenib and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. Clin. Cancer Res. 12, 144-151 (2006).
61. Richly, H. et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann. Oncol. 17, 866-873 (2006).
62. Awada, A. et al. A Phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with Taxotere in patients with advanced solid tumors. Poster presentation Am. Assoc. Cancer Res.-Natl Cancer Inst.-Eur. Organiz. Res. Treat. Cancer. Geneva, Switzerland (2004).
63. Steinbild, S. et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J. Clin. Oncol. 23, 3115 (2005).
64. Eisen, T. et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J. Clin. Oncol. 23, 7508 (2005).
65. Gollob, J. et al. Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma. Eur. J. Cancer Supplements 3, 226 (2005).
66. Robert, C. et al. Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2a in patients with unresectable and/ or metastatic renal cell carcinoma and malignant melanoma. Eur. J. Cancer Supplements 3, 254 (2005).
67. Hainsworth, J. D. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896 (2005).
68. Takahashi, A. et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 54, 4233-4237 (1994).
69. Smith, K. et al. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 65, 5221-5230 (2005).
70. Gunaratnam, L. et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278, 44966-44974 (2003).
71. Ratain, M. J. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
72. Escudier, B. et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur. J. Cancer Supplements 3, 226 (2005).
73. Motzer, R. J. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22, 454-463 (2004).
74. Abou-Alfa, G. K. et al. Phase II biomarker analysis of sorafenib (BAY 43-9006) in patients with advanced hepatocellular carcinoma. Poster presentation Am. Assoc. Cancer Res.-Natl Cancer Inst.-Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
75. Gatzemeier, U. et al. Phase II trial of single-agent sorafenib in patients with advanced non-small-cell lung carcinoma. J. Clin. Oncol. 24, 364s (2006).
76. Kloos, R. et al. Significant clinical and biologic activity of RAF/ VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. J. Clin. Oncol. 24, 288s (2006).
77. Steinbild, S. et al. Phase II study of sorafenib (BAY43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research - EWIV (CESAR). J. Clin. Oncol. 24, 144s (2006).
78. Dahut, W. L. et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J. Clin. Oncol. 24, 218s (2006).
79. Moreno-Aspitia, A. et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J. Clin. Oncol. 24, 577 (2006).
80. Wright, J. J., Zerivitz, K. & Gravell, A. Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1. Oncology (Williston Park) 19, 499-502 (2005).
81. Lorigan, P. et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J. Clin. Oncol. 24, 8012 (2006).
82. Sosman, J. et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J. Clin. Oncol. 24, 128s (2006).
83. Azad, N. S. et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J. Clin. Oncol. 24, 121s (2006).
84. Elting, J. et al. Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. Proc. Am. Assoc. Cancer Res. 47, A2909 (2006).
85. Advani, A. S. C-kit as a target in the treatment of acute myelogenous leukemia. Curr. Hematol. Rep. 4, 51-58 (2005).
86. Markovic, A., MacKenzie, K. L. & Lock, R. B. FLT-3: A new focus in the understanding of acute leukemia. Int. J. Biochem. Cell Biol. 37, 1168-1172 (2005).
87. Chen, L. L. et al. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep. 7, 293-299 (2005).
88. Kodama, Y. et al. The RET proto-oncogene: A molecular therapeutic target in thyroid cancer. Concer Sci. 96, 143-148 (2005).
89. Flaherty, K. T. et al. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 23, 201s (2005).
90. Blumenschein, G. R. et al. Phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in relapsed or refractory advanced non-small cell lung cancer. Poster presentation Am. Assoc. Cancer Res.-Natl Cancer Inst.-Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
91. Salvatore, G. et al. B-RAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 12, 1623-1629 (2006).
92. Levy, J. et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc. Am. Assoc. Cancer Res. 47, 213-214 (2006).